Janneke van de Kamp | CEO
Norgine

Janneke van der Kamp is Chief Executive Officer of Norgine, a mid-sized EU-based pharmaceutical company with 1,500 employees and approximately $600 million in annual sales. Innovation drives Norgine’s mission to deliver medicines that change lives. The company targets unmet medical needs across a broad spectrum — from common conditions like constipation to rare and severe diseases such as childhood cancer. Through innovative development, commercialisation and manufacturing capabilities, and strategic partnerships, Norgine is committed to navigating complex pathways to accelerate and expand the reach of life-changing medicines across Europe, Australia, and New Zealand. Janneke joined Norgine in 2024, bringing over two decades of leadership experience in the pharmaceutical industry. She began her career in strategy consulting before joining Novartis, where she held senior roles including General Manager, Global Neurosciences Franchise Head, and Global Head of Product and Portfolio Strategy. Her final role at Novartis was Head of Pharma Region Europe, where she led a team of 8,000 people and oversaw a $9 billion business. Prior to joining Norgine, Janneke served as Chief Commercial Officer at Grünenthal. She holds an M.Sc. in Chemistry and an MBA from INSEAD. Under Janneke’s leadership, Norgine is accelerating its mission to bring life-changing medicines to more patients, more quickly. She is driving a strategy that combines in-house innovation with strategic partnerships, enabling the company to expand its portfolio and pursue assets in areas of high unmet need. With a well-funded business model and deep regional expertise, Norgine continues to be a trusted partner for biotech and pharmaceutical companies seeking to navigate complex pathways across Europe and ANZ. Janneke is also deeply committed to building a culture where people thrive. Together with her leadership team, she is focused on creating a workplace where colleagues feel valued, supported, and inspired — removing barriers and enabling teams to deliver meaningful healthcare impact. Her leadership philosophy centres on empowerment, collaboration, and purpose-driven growth. A regular speaker at industry events, Janneke is recognised for her strategic insight and her commitment to advancing access to innovative therapies. She continues to champion Norgine’s vision: to deliver innovation that transforms lives, one patient at a time. Janneke van der Kamp is Chief Executive Officer of Norgine, a mid-sized EU-based pharmaceutical company with 1,500 employees and approximately $600 million in annual sales. Innovation drives Norgine’s mission to deliver medicines that change lives. The company targets unmet medical needs across a broad spectrum — from common conditions like constipation to rare and severe diseases such as childhood cancer. Through innovative development, commercialisation and manufacturing capabilities, and strategic partnerships, Norgine is committed to navigating complex pathways to accelerate and expand the reach of life-changing medicines across Europe, Australia, and New Zealand. Janneke joined Norgine in 2024, bringing over two decades of leadership experience in the pharmaceutical industry. She began her career in strategy consulting before joining Novartis, where she held senior roles including General Manager, Global Neurosciences Franchise Head, and Global Head of Product and Portfolio Strategy. Her final role at Novartis was Head of Pharma Region Europe, where she led a team of 8,000 people and oversaw a $9 billion business. Prior to joining Norgine, Janneke served as Chief Commercial Officer at Grünenthal. She holds an M.Sc. in Chemistry and an MBA from INSEAD. Under Janneke’s leadership, Norgine is accelerating its mission to bring life-changing medicines to more patients, more quickly. She is driving a strategy that combines in-house innovation with strategic partnerships, enabling the company to expand its portfolio and pursue assets in areas of high unmet need. With a well-funded business model and deep regional expertise, Norgine continues to be a trusted partner for biotech and pharmaceutical companies seeking to navigate complex pathways across Europe and ANZ. Janneke is also deeply committed to building a culture where people thrive. Together with her leadership team, she is focused on creating a workplace where colleagues feel valued, supported, and inspired — removing barriers and enabling teams to deliver meaningful healthcare impact. Her leadership philosophy centres on empowerment, collaboration, and purpose-driven growth. A regular speaker at industry events, Janneke is recognised for her strategic insight and her commitment to advancing access to innovative therapies. She continues to champion Norgine’s vision: to deliver innovation that transforms lives, one patient at a time.